nalidixic acid (neggram) Report issue

Small molecule Approved FDA Priority Review FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Nalidixic acid is a quinolone antibacterial indicated for the treatment of urinary tract infections. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are generally resistant to the drug. It is suggested that nalidixic acid acts by inhibiting bacterial DNA gyrase.   NCATS

Chemistry

More Chemistry

Pharmacology

Alternative names

1,4-dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid | 1-aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure | 1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid | 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid | 1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid | 3-carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one | acide nalidixique | acido nalidixico | acidum nalidixicum | nalidic acid | nalidixane | nalidixate | nalidixic acid | nalidixic acid citrated | nalidixic acid sodium | nalidixic acid sodium salt | nalidixinic acid | nalidixinsäure | nalix | neggram | neg gram | negram | uriben | uroneg | win-18320 | wintomylon

Organizations (3)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Urinary Tract Infections (approved 1964)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue